Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour

Oral Oncology

Volumn 40, Issue 2, 2004, Pages 228-230

  Raguse, Jan Dirk ^a   Gath, Hans Joachim ^a   Bier, Jürgen ^a   Riess, Hanno ^a   Oettle, Helmut ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antiangiogenesis; Cilengitide; EMD 121974; Head and neck tumour; Target therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; CILENGITIDE; CISPLATIN; CYCLOPEPTIDE; DOCETAXEL; GEMCITABINE; RADIOSENSITIZING AGENT;

ADULT; ANGIOGRAPHY; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DRUG EFFECT; EATING; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; JAW CANCER; MAINTENANCE THERAPY; MALE; NECK DISSECTION; ODOR; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SURGICAL TECHNIQUE; TOXICITY; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 0346158521     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2003.08.003     Document Type: Article

References (4)

1. Dechantsreiter M.A., Planker E., Matha B., Lohof E., Holzemann G., Jonczyk A.et al. N-methylated RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J. Med. Chem. 42:1999;3033-3040.
2. Mitjans F., Meyer T., Fittschen C., Goodman S., Jonczyk A., Marshall J.F.et al. In vivo therapy of malignant melanoma by means of antagonists of alpha v integrins. Int J Cancer. 87:2000;716-723.
3. 3 antagonists promote tumour regression by inducing apoptosis od angiogenic blood vessels. Cell. 79:1994;1157-1164.
4. Eskens F., Dumez H., Verweij J., Perschl A., Kovar A., Brindley C.et al. Phase I pharmacologic study of EMD 121974 an inhibitor of angiogenesis in patients with solid tumours. Proc Am Soc Clin Oncol. 19:2000;206a. abstract 801.